Zobrazeno 1 - 10
of 100
pro vyhledávání: '"E. Quinaux"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marc Buyse, Martine Piccart-Gebhart, Dennis J. Slamon, E. Quinaux, Dimitris Mavroudis, Suzette Delaloge, Norman Wolmark, Pierre Squifflet, Bryan P. Schneider, Edith A. Perez, Tomasz Burzykowski, Everardo D. Saad
Publikováno v:
The Lancet Oncology. 20:361-370
Summary Background Although frequently used as a primary endpoint, disease-free survival has not been validated as a surrogate for overall survival in early breast cancer. We investigated this surrogacy in the adjuvant setting of treatment with anti-
Autor:
Ivonne Villalobos, Wolfgang Eiermann, E. Quinaux, V. Valero, J.P. Crown, Guido Sauter, Joan Seoane, Christina Curtis, Tadeusz Pienkowski, Nicholas J. Robert, M. Martin, Yanling Ma, Michael F. Press, V Bee, DJ Slamon, John R. Mackey, R Guzman
Publikováno v:
Cancer Research. 79:PD3-11
Background. The ASCO-CAP guidelines for HER2 testing by fluorescence in situ hybridization (FISH) have a category, referred to as “equivocal” (average HER2 copies per tumor cell >4-6 with HER2/CEP17 ratio Methods. We retrospectively assessed the
Autor:
Dennis J. Slamon, Tadeusz Pienkowski, Valerie Bee, E. Quinaux, Yanling Ma, Marc Buyse, Anaamika Campeau, Guido Sauter, Michael F. Press, Nicholas J. Robert, Wolfgang Eiermann, Denice D. Tsao-Wei, Miguel Martin, Martina Mirlacher, J.P. Crown, Hélène Fourmanoir, Ivonne Villalobos, Mary Ann Lindsay, John R. Mackey, Vicente Valero
Publikováno v:
Journal of Clinical Oncology
Purpose ASCO and the College of American Pathologists (ASCO-CAP) recently recommended further changes to the evaluation of human epidermal growth factor receptor 2 gene (HER2) amplification by fluorescent in situ hybridization (FISH). We retrospectiv
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Thierry André, A. de Gramont, L. M. Soveri, Tuija Poussa, Kethe Hermunen, Pia Österlund, E. Quinaux, Petri Bono
Publikováno v:
European Journal of Cancer. 50:2966-2974
Background Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival. We studied whether haematological (leucopenia, neutropenia, thrombocytopenia) or non-haematological (mucos
Autor:
Marc Buyse, Pierre Squifflet, Elisabeth Coart, Cornelis J. A. Punt, E. Quinaux, Everardo D. Saad
Publikováno v:
Clinical trials (London, England), 14(5), 499-506. SAGE Publications Ltd
Background/aims Considerable human and financial resources are typically spent to ensure that data collected for clinical trials are free from errors. We investigated the impact of random and systematic errors on the outcome of randomized clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6244abcb5b25225c1929a2b5d5b02a4
https://pure.amc.nl/en/publications/the-impact-of-data-errors-on-the-outcome-of-randomized-clinical-trials(7fa93448-b9e9-4944-8dc8-823ca7b1e642).html
https://pure.amc.nl/en/publications/the-impact-of-data-errors-on-the-outcome-of-randomized-clinical-trials(7fa93448-b9e9-4944-8dc8-823ca7b1e642).html
Autor:
L. Zelek, Pascal Piedbois, Daniel Serin, E. Teissier, Marc Buyse, E. Quinaux, Frank Priou, Catherine Delbaldo, M. Mousseau, P. Laplaige, S. Greget, J. F. Berdah, B. Audhuy
Publikováno v:
European Journal of Cancer. 50:23-30
Background Standard adjuvant chemotherapy regimens for patients with node positive (N+) breast cancer consisted of anthracycline followed by taxane. The European Association for Research in Oncology embarked in 2000 on a phase III trial comparing 6 c
Autor:
Valerie Bee, Vicente Valero, Jose A. Seoane, Ivonne Villalobos, Dennis J. Slamon, Christina Curtis, Yanling Ma, Tadeusz Pienkowski, John R. Mackey, Michael F. Press, E. Quinaux, John Crown, Guido Sauter, Roberta Guzman, Nicholas J. Robert, Miguel Martin, Wolfgang Eiermann
Publikováno v:
JAMA Oncology
Key Points Questions How does one assess the status of HER2 ISH-equivocal breast cancers as either HER2 positive or HER2 negative for treatment purposes, and are the use of alternative controls, as recommended by the 2013/2014 American Society of Cli
Autor:
Denis Larsimont, Bo Nordenskjöld, E. de Azambuja, Richard D. Gelber, I. Steinberg, Martine Piccart-Gebhart, J. Gutierrez, M. Margeli Vila, Prudence A. Francis, A. Di Leo, Catherine Oakman, L. Punzalan, Marc Buyse, Martin Andersson, Vernon Harvey, Beat Thürlimann, Giuseppe Viale, Raimund Jakesz, Patrizia Dell'Orto, John Crown, E. Quinaux
Publikováno v:
Annals of Oncology. 24:1203-1211
Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At